Cephalosporins' Cross-Reactivity and the High Degree of Required Knowledge. Case Report and Review of the Literature.
R1 side-chain
R2 side-chain
anaphylactic shock
cefepime
ceftriaxone
immunohistochemistry
liability
medical malpractice
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
25 Apr 2020
25 Apr 2020
Historique:
received:
02
04
2020
revised:
14
04
2020
accepted:
23
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
30
4
2020
Statut:
epublish
Résumé
Antibiotic cross-reactivity represents a phenomenon of considerable interest as well as antibiotic resistance. Immediate reactions to cephalosporins are reported in the literature with a prevalence of only 1%-3% of the population, while anaphylactic reactions are rarely described (approximately 0.0001%-0.1%) as well as fatalities. Allergic reaction to cephalosporins may occur because of sensitization to unique cephalosporin haptens or to determinants shared with penicillins. Cross-reactivity between cephalosporins represents, in fact, a well-known threatening event involving cephalosporins with similar or identical R1- or R2-side chains. The present report describes the case of a 79-year-old man who suddenly died after intramuscular administration of ceftriaxone. Serum dosage of mast cell tryptase from a femoral blood sample at 3 and 24 hours detected values of 87.7μg/L and 93.5μg/L, respectively (cut-off value 44.3 μg/L); the serum-specific IgE for penicillins, amoxicillin, cephaclor and also for the most common allergens were also determined. A complete post-mortem examination was performed, including gross, histological and immunohistochemical examination, with an anti-tryptase antibody. The cause of death was identified as anaphylactic shock: past administrations of cefepime sensitized the subject to cephalosporins and a fatal cross-reactivity of ceftriaxone with cefepime occurred due to the identical seven-position side chain structure in both molecules. The reported case offers food for thought regarding the study of cross-reactivity and the need to clarify the predictability and preventability of the phenomenon in fatal events.
Identifiants
pubmed: 32344946
pii: antibiotics9050209
doi: 10.3390/antibiotics9050209
pmc: PMC7277108
pii:
doi:
Types de publication
Case Reports
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Pharmacotherapy. 2004 May;24(5):668-72
pubmed: 15162902
Curr Pharm Biotechnol. 2019;20(8):625-634
pubmed: 30961487
Clin Exp Allergy. 2015 Feb;45(2):300-27
pubmed: 25623506
Ann Intern Med. 2004 Jul 6;141(1):16-22
pubmed: 15238366
J Mol Recognit. 2003 May-Jun;16(3):148-56
pubmed: 12833570
J Allergy Clin Immunol. 2000 Dec;106(6):1177-83
pubmed: 11112903
Clin Exp Allergy. 2002 Nov;32(11):1644-50
pubmed: 12569987
J Allergy Clin Immunol. 2006 Feb;117(2):404-10
pubmed: 16461141
Lancet. 2019 Jan 12;393(10167):183-198
pubmed: 30558872
J Allergy Clin Immunol. 2015 Nov;136(5):1426-8
pubmed: 26388313
Diagn Microbiol Infect Dis. 2007 Mar;57(3 Suppl):13S-18S
pubmed: 17349459
Intern Med J. 2019 Aug;49(8):985-993
pubmed: 30667130
Ann Allergy Asthma Immunol. 2014 May;112(5):404-12
pubmed: 24767695
Int Forum Allergy Rhinol. 2015 Feb;5(2):104-10
pubmed: 25332200
N Engl J Med. 2001 Sep 13;345(11):804-9
pubmed: 11556301
Br J Clin Pharmacol. 2011 May;71(5):684-700
pubmed: 21480948
J Mol Recognit. 1996 Jul-Aug;9(4):287-96
pubmed: 9131470
J Allergy Clin Immunol. 2015 Mar;135(3):745-52.e5
pubmed: 25262461
Clin Rev Allergy Immunol. 2013 Aug;45(1):131-42
pubmed: 23546989
Curr Pharm Biotechnol. 2017;18(3):274-281
pubmed: 28176638
Allergy. 2005 Dec;60(12):1545-6
pubmed: 16266391
Int Arch Allergy Appl Immunol. 1990;92(4):439-44
pubmed: 2083978
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
Clin Exp Allergy. 2005 Sep;35(9):1234-42
pubmed: 16164453
Curr Pharm Biotechnol. 2017;18(3):194-203
pubmed: 28240172
J Allergy Clin Immunol. 2016 Apr;137(4):1148-1153
pubmed: 26688516
Curr Pharm Biotechnol. 2017;18(3):263-273
pubmed: 28176637
Ann Allergy Asthma Immunol. 2010 Oct;105(4):259-273
pubmed: 20934625
Sci Rep. 2018 Aug 24;8(1):12811
pubmed: 30143737
Allergy. 2018 Sep;73(9):1833-1841
pubmed: 29517808
Clin Exp Allergy. 2001 Mar;31(3):438-43
pubmed: 11260156
Curr Pharm Biotechnol. 2019;20(8):643-652
pubmed: 30961489
J Fam Pract. 2006 Feb;55(2):106-12
pubmed: 16451776
J Allergy Clin Immunol. 2015 Sep;136(3):685-691.e3
pubmed: 25930196
Allergy Asthma Proc. 2004 Jan-Feb;25(1):23-6
pubmed: 15055557
Immunol Allergy Clin North Am. 2004 Aug;24(3):463-76, vi-vii
pubmed: 15242721
Allergy. 2016 Sep;71(9):1305-13
pubmed: 26970431
J Allergy Clin Immunol. 2014 Mar;133(3):790-6
pubmed: 24188976
Qual Saf Health Care. 2004 Aug;13(4):306-14
pubmed: 15289635
JAMA. 1966 Oct 24;198(4):345-8
pubmed: 5953252
Ann Allergy Asthma Immunol. 2018 Nov;121(5):530-536
pubmed: 29551402
Allergy. 2003 Jun;58(6):537-8
pubmed: 12757464
Curr Pharm Des. 2006;12(26):3335-45
pubmed: 17017928
Curr Pharm Biotechnol. 2017;18(3):242-252
pubmed: 28183244
Chem Res Toxicol. 2011 May 16;24(5):706-17
pubmed: 21425867
Pharmacy (Basel). 2019 Jul 29;7(3):
pubmed: 31362351
Allergy. 2004 Feb;59(2):239-41
pubmed: 14763949
Curr Allergy Asthma Rep. 2016 Mar;16(3):24
pubmed: 26898316
PLoS One. 2016 Jul 20;11(7):e0159406
pubmed: 27438379
Allergy. 2010 Jan;65(1):130-1
pubmed: 20078505
Clin Exp Allergy. 2011 Nov;41(11):1602-8
pubmed: 22093010
Pediatrics. 2005 Apr;115(4):1048-57
pubmed: 15805383
Clin Infect Dis. 2015 Sep 1;61(5):741-9
pubmed: 25991471
Curr Opin Allergy Clin Immunol. 2002 Aug;2(4):297-300
pubmed: 12130943
J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1532-1542
pubmed: 28843343
J Allergy Clin Immunol. 2012 Dec;130(6):1442-2.e5
pubmed: 23195529